Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Capmatinib (Tabrecta) - To treat patients with non small cell lungcancer Drug Approval Package: TABRECTA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TABRECTA Company: Novartis Pharmaceuticals Corporation Application Number: 213591 Approval Date: 05/06/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF
Tepotinib in Non-Small-Cell LungCancer with MET Exon 14 Skipping Mutations. A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lungcancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced (...) of the previous therapy received for advanced or metastatic disease. Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. A molecular response, as measured in circulating free DNA, was observed in 67% of the patients with matched liquid-biopsy samples at baseline and during treatment.Among patients
eUpdate – Early and Locally Advanced Non-Small-Cell LungCancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell LungCancer Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. MINIMAL Requirements: , , , , , Search eUpdate – Early and Locally Advanced Non-Small-Cell LungCancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell LungCancer (NSCLC) Treatment (...) cancer (NSCLC) who have not progressed following chemoradiotherapy whose tumours express programmed death-ligand 1 (PD-L1) on ≥1% of tumour cells, although the latter was a post hoc subgroup analysis. The recommendation is based on the phase III PACIFIC trial, in which the PD-L1 inhibitor durvalumab, commenced 1–42 days post chemoradiotherapy, improved both progression-free survival [PFS; median PFS 16.8 versus 5.6 months; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.42–0.65, P <0.0001
. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 212 2 Information about lorlatinib Information about lorlatinib Marketing authorisation indication Marketing authorisation indication 2.1 Lorlatinib (Lorviqua, Pfizer) as monotherapy is indicated for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non- small cell lungcancer (NSCLC) whose disease has progressed after: • alectinib or ceritinib as the first ALK (...) that there was a significant unmet need for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lungcancer (NSCLC), even though 4 ALK tyrosine kinase inhibitor (TKI) treatments are available. The committee noted that neither crizotinib nor ceritinib are preferred for untreated disease since the availability of alectinib. Brigatinib has been approved for previously treated disease only after crizotinib. If alectinib's treatment effect wanes the only current option is chemotherapy. ALK TKI treatments
, which can hinder early diagnosis and treatment. 4, 5 Lungcancer presentations can also be complex, due to co-morbidities or plausible alternative diagnoses. 6 Lungcancer symptoms can present in a similar manner to other conditions such as chronic obstructive pulmonary disease (COPD), chronic heart failure and coronary heart disease. 7 Therefore, it is important to increase awareness of lungcancer symptoms and risk factors, and to provide all health professionals with the most recent evidence (...) with symptoms or signs consistent with lungcancer. The Guide does not provide advice on the following: • adults with mesothelioma • adults with lung metastases arising from primary cancer originating outside the lung • children (younger than 18 years) with lungcancer • adults with rare lungtumours • adults with benign lungtumours, and • adults being screened for lungcancer. For more information on the potential role of screening for asymptomatic patients, visit Cancer Australia’s lungcancer screening
The association of lungcancer with smoking can lead to lungcancer patients feeling stigmatised, contributing to delays in help-seeking for symptoms 4,5 and psychological distress. 6 Risk factors for lungcancer Lifestyle factors - current or former tobacco smoking Environmental or occupational factors - passive smoking - occupational exposures e.g. radon, asbestos, diesel exhaust, silica - air pollution Personal factors - increasing age - family history of lungcancer - chronic lungdisease e.g. chronic (...) obstructive pulmonary disease (COPD), pulmonary fibrosis - personal history of cancer e.g. lungcancer, head and neck cancer, bladder cancer Symptoms and signs of lungcancer Symptoms can present in a similar manner to other conditions such as COPD, chronic heart failure and coronary heart disease. 7 Please refer to the flow chart overleaf for symptoms and signs of lungcancer, recommended investigations and referrals, and timeframes for referral. 80 90 100 70 60 50 40 30 20 10 Stage at diagnosis and 5
screening, defer surveillance imaging of lung nodules, and minimize nonurgent interventions during the evaluation of lung nodules and stage I non-small cell lungcancer. INTERPRETATION: There was consensus that during the COVID-19 pandemic, it is appro- priatetodeferenrollmentinlungcancerscreeningandmodifytheevaluationoflungnodules ABBREVIATIONS: CDC = Centers for Disease Control and Prevention; COVID-19 = coronavirus disease 19; Lung-RADS = Lung CT Screening Reporting and Data System; pCA = probability (...) : consensus statement; COVID-19; lungcancer screening; lung nodule In some parts of the world, the coronavirus disease 2019 (COVID-19) pandemic has stressed the health- care systems close to or even past their breaking point. Rightfully, much of the attention to date has focused on the immediate needs of patients suffering from the disease, particularly those who are critically ill. The strain on health-care systems and the need to control the virus using containment (testing and isolating cases
Association between polymorphisms of epidermal growth factor 61 and susceptibility of lungcancer: A meta-analysis. To explore the association between epidermal growth factor (EGF) 61A/G polymorphism and lung cancer.All eligible case-control studies published up to August, 2019 were identified by searching PubMed, The excerpta medica database, China Academic Journals Full-text Database, China Biology Medicine, China National Knowledge Infrastructure, China Science and Technology Journal (...) Database, and Wanfang databases. Two researchers independently identified the literature, extracted data, and evaluated quality according to inclusion and exclusion criteria. Meta-analysis was performed by Stata 15.0.A total of 6 studies is included, including 1487 cases and 2044 control subjects. Compared with allele A, allele G was considered to have no association with the risk of lungcancer, odds ratio = 1.07 (95% confidence interval: 0.98-1.15). GG recessive genotype, GG + GA dominant genotype
Clinicopathological and prognostic significance of thyroid transcription factor-1 expression in small cell lungcancer: A systemic review and meta-analysis. To explore the association of thyroid transcription factor-1 (TTF-1) expression status with clinicopathological characteristics and survival of patients with small cell lungcancer (SCLC).A comprehensive literature search was conducted to identify potentially relevant studies in several electronic databases, including EMBASE, PubMed, Web
cancer. The pooled OR of eighteen studies for lungcancer was 0·58 (95 % CI 0·45, 0·74) by comparing the highest category with the lowest category of carrot consumption. Based on subgroup analyses for the types of lungcancer, we pooled that squamous cell carcinoma (OR 0·52, 95 % CI 0·19, 1·45), small-cell carcinoma (OR 0·43, 95 % CI 0·12, 1·59), adenocarcinoma (OR 0·34, 95 % CI 0·15, 0·79), large-cell carcinoma (OR 0·40, 95 % CI 0·10, 1·57), squamous and small-cell carcinoma (OR 0·85, 95 % CI 0·45 (...) , 1·62), adenocarcinoma and large-cell carcinoma (OR 0·20, 95 % CI 0·02, 1·70) and mixed types (OR 0·61, 95 % CI 0·46, 0·81). Exclusion of any single study did not materially alter the pooled OR. Integrated epidemiological evidence from observational studies supported the hypothesis that carrot consumption may decrease the risk of lungcancer, especially for adenocarcinoma.
The Hepatorenal Toxicity and Tumor Response of Chemotherapy With or Without Aidi Injection in Advanced LungCancer: A Meta-Analysis of 80 Randomized Controlled Trials. Chemotherapy-induced hepatorenal toxicity often decreases tolerance for further therapies and results in poor quality of life and prognosis for patients with lungcancer. In this meta-analysis, all related studies were systematically re-evaluated to determine whether Aidi injection relieves hepatorenal toxicity and improves tumor (...) days per cycle, and 2 to 3 cycles of Aidi injection with chemotherapy resulted in a low incidence of hepatorenal toxicity. All of the results were robust, and their quality was moderate.The moderate evidence indicates that Aidi injection with chemotherapy may improve tumor response and result in a low incidence of hepatorenal toxicity in patients with lungcancer. Aidi injection may relieve hepatorenal toxicity and exhibit an important protective effect against chemotherapy-induced hepatorenal
Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lungcancer? A systematic review and meta-analysis. To perform a systematic review and meta-analysis evaluating usefulness of high-risk CT features (HRFs) on follow-up CT in detecting local recurrence after stereotactic body radiation therapy (SBRT) in lungcancer patients.Pubmed and EMBASE were searched up to January 11th, 2019. We included studies that differentiated local recurrence from post (...) -SBRT changes after SBRT on follow-up CT in lungcancer patients. Methodological quality was assessed using QUADAS-2. The association between HRFs and local recurrence were pooled in the form of odds ratio (OR) using the random effects model. Heterogeneity was examined by the Inconsistency index (I2).Eight studies were included, consisting of 356 lungcancer patients. The overall prevalence of patients with local recurrence was 18.8 % (67/356). Compared with post-SBRT changes, local recurrence after
Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lungcancer. In recent years, many studies on the relationship between the expression of microRNA-126(miR-126) and the diagnostic and prognostic value of non-small cell lungcancer (NSCLC)have been made, but the results were still controversial.The aim is to explore the expression of miR-126 and the diagnosis and prognosis value of NSCLC, and to provide relevant evidence for clinical diagnosis and treatment
Identifying optimal first-line interventions for advanced non-small cell lungcarcinoma according to PD-L1 expression: a systematic review and network meta-analysis. This network meta-analysis (NMA), based on one phase II and nine phase III studies, involving 6,124 patients with metastatic NSCLC, indirectly compares Atezolizumab + Bevacizumab + chemotherapy (ABC), Atezolizumab + chemotherapy (AC), Pembrolizumab + chemotherapy (PC), Pembrolizumab alone, Bevacizumab + chemotherapy (BC
Effects of Breathing Exercises on Patients With LungCancer. To evaluate the effects of breathing exercises on dyspnea, six-minute walk distance (6MWD), anxiety, and depression in patients with lung cancer.A systematic literature search of the Cochrane Library, Web of Science, Embase®, PubMed®, Weipu, Wanfang, and Chinese National Knowledge Infrastructure databases was performed for publications dated prior to April 6, 2018.The meta-analysis was performed using Review Manager and Stata.15